SGLT-2 inhibitors in non-alcoholic fatty liver disease patients with type 2 diabetes mellitus: A systematic review

doi:10.4239/wjd.v10.i2.114

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 10, Issue 2

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (11479)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-1) series, Tables (1-18) series.

Item

Count

PDF

833

WORD

326

HTML

5909

Figures (1-1)

279

Tables (1-18)

257

Sum=7604

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

533

Download

803

Sum=1336

Publishing Process of This Article

Item

Count

Browse

919

Download

1620

Sum=2539

Feb 15, 2019 (publication date) through Dec 25, 2024

Times Cited of This Article

Times Cited (63)

Journal Information of This Article

Publication Name

World Journal of Diabetes

ISSN

1948-9358

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Systematic Reviews

World J Diabetes. Feb 15, 2019; 10(2): 114-132
Published online Feb 15, 2019. doi: 10.4239/wjd.v10.i2.114

Table 11 Change in fasting plasma glucose in individual studies

Study	Fasting plasma glucose (mg/dL)			P value	P value between groups
Study	Group	Baseline	Study completion	P value	P value between groups
Kuchay et al[11]	Empagliflozin	173.0 (44.0)	124.0 (17.0)	< 0.001	0.85
Kuchay et al[11]	Control	176.0 (57.0)	120.0 (19.0)	< 0.0001	0.85
Ito et al[12]	Ipragliflozin	160.1 (38.7)	136.5 (26.7)	< 0.05	0.785
Ito et al[12]	Pioglitazone	169.4 (50.9)	139.0 (26.6)	< 0.05	0.785
Shibuya et al[13]	Luseogliflozin	127.0 (116.0, 136.0)	125.0 (113.0, 138.0)	0.87	0.583
Shibuya et al[13]	Metformin	147.0 (126.0, 161.0)	134.0 (122.0, 145.0)	0.32	0.583
Eriksson et al[14]	Placebo	169.2 (29.7)	+6.7 (14.8)¹	-	-
	Omega-3 CA	162.4 (26.6)	+3.8 (19.3)¹	-	Non-significant²
	Dapagliflozin	161.8 (33.3)	-17.6 (26.8)¹	-	< 0.05²
	O + D	168.8 (35.5)	-16.4 (36.0)¹	-	< 0.05²
Ohki et al[15]	Ipragliflozin	162.0 (135.0-189.0)	135.0 (120.0-166.0)	0.3	-
Seko et al[16]	SGLT-2 inhibitor	125.0 (6.0)	116.6 (4.2)	0.07	Non-significant
Seko et al[16]	Sitagliptin	114.6 (7.0)	134.0 (10.5)	0.067	Non-significant
Sumida et al[18]	Luseogliflozin	142.0 (30.3)	135.4 (25.6)	0.04	-

¹Change from baseline.

²Compared to placebo.

CA: Carboxylic acid; O + D: Omega-3 carboxylic acid + Dapagliflozin; SGLT-2: Sodium glucose cotransporter-2.

Citation: Raj H, Durgia H, Palui R, Kamalanathan S, Selvarajan S, Kar SS, Sahoo J. SGLT-2 inhibitors in non-alcoholic fatty liver disease patients with type 2 diabetes mellitus: A systematic review. World J Diabetes 2019; 10(2): 114-132
URL: https://www.wjgnet.com/1948-9358/full/v10/i2/114.htm
DOI: https://dx.doi.org/10.4239/wjd.v10.i2.114